176 related articles for article (PubMed ID: 31357769)
1. [Research progress of deubiquitinating enzyme CYLD to regulate liver-related diseases].
Yang X; An DJ; Gao CC; Qin HY
Zhonghua Gan Zang Bing Za Zhi; 2019 Jun; 27(6):477-480. PubMed ID: 31357769
[TBL] [Abstract][Full Text] [Related]
2. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
3. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
4. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
5. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
6. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
7. The K48-K63 Branched Ubiquitin Chain Regulates NF-κB Signaling.
Ohtake F; Saeki Y; Ishido S; Kanno J; Tanaka K
Mol Cell; 2016 Oct; 64(2):251-266. PubMed ID: 27746020
[TBL] [Abstract][Full Text] [Related]
8. Potential role of CYLD (Cylindromatosis) as a deubiquitinating enzyme in vascular cells.
Takami Y; Nakagami H; Morishita R; Katsuya T; Hayashi H; Mori M; Koriyama H; Baba Y; Yasuda O; Rakugi H; Ogihara T; Kaneda Y
Am J Pathol; 2008 Mar; 172(3):818-29. PubMed ID: 18245814
[TBL] [Abstract][Full Text] [Related]
9. Negative regulation of JNK signaling by the tumor suppressor CYLD.
Reiley W; Zhang M; Sun SC
J Biol Chem; 2004 Dec; 279(53):55161-7. PubMed ID: 15496400
[TBL] [Abstract][Full Text] [Related]
10. CYLD: a multifunctional deubiquitinase.
Glittenberg M; Ligoxygakis P
Fly (Austin); 2007; 1(6):330-2. PubMed ID: 18820455
[TBL] [Abstract][Full Text] [Related]
11. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E; Hatzivassiliou E; Tsichritzis T; Farmer H; Ashworth A; Mosialos G
Nature; 2003 Aug; 424(6950):793-6. PubMed ID: 12917689
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of CYLD downregulation in breast cancer.
Hayashi M; Jono H; Shinriki S; Nakamura T; Guo J; Sueta A; Tomiguchi M; Fujiwara S; Yamamoto-Ibusuki M; Murakami K; Yamashita S; Yamamoto Y; Li JD; Iwase H; Ando Y
Breast Cancer Res Treat; 2014 Feb; 143(3):447-57. PubMed ID: 24398777
[TBL] [Abstract][Full Text] [Related]
13. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
14. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
15. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A; Chable-Bessia C; Cantarella G; Israël A; Wallach D; Courtois G
Nature; 2003 Aug; 424(6950):801-5. PubMed ID: 12917691
[TBL] [Abstract][Full Text] [Related]
16. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
Kobayashi T; Masoumi KC; Massoumi R
Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinases in the regulation of NF-κB signaling.
Harhaj EW; Dixit VM
Cell Res; 2011 Jan; 21(1):22-39. PubMed ID: 21119682
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F; Sowa ME; Nalepa G; Gygi SP; Harper JW; Elledge SJ
Proc Natl Acad Sci U S A; 2007 May; 104(21):8869-74. PubMed ID: 17495026
[TBL] [Abstract][Full Text] [Related]
19. Mutated cylindromatosis gene affects the functional state of dendritic cells.
Bros M; Dexheimer N; Besche V; Masri J; Trojandt S; Hövelmeyer N; Reissig S; Massoumi R; Grabbe S; Waisman A; Reske-Kunz AB
Eur J Immunol; 2010 Oct; 40(10):2848-57. PubMed ID: 20836156
[TBL] [Abstract][Full Text] [Related]
20. Expression of CYLD and NF-kappaB in human cholesteatoma epithelium.
Byun JY; Yune TY; Lee JY; Yeo SG; Park MS
Mediators Inflamm; 2010; 2010():796315. PubMed ID: 20414373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
